Eight-year follow-up data from the HERA trial confirm that one-year of adjuvant trastuzumab (Herceptin) is better than 2 years -- or none in HER2-positive breast cancer. Bruce Jancin of IMNG Medical Media interviews Dr. Martine Piccart at the San Antonio Breast Cancer Symposium, where she presented encouraging results from this large multinational effort.